Synlogic, Inc. (SYBX) Bundle
An Overview of Synlogic, Inc. (SYBX)
General Summary of Synlogic, Inc. (SYBX)
Synlogic, Inc. is a clinical-stage synthetic biotic medicine company headquartered in Cambridge, Massachusetts. The company focuses on developing novel therapies using synthetic biology platform technology.
Company Products and Services
Synlogic's primary focus areas include:
- Synthetic biotic medicines for metabolic disorders
- Precision medicines targeting rare genetic diseases
- Immuno-oncology therapeutic development
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.7 million |
| Net Loss | $56.3 million |
| Cash and Equivalents | $87.4 million |
| Research and Development Expenses | $41.2 million |
Key Pipeline Assets
| Program | Indication | Development Stage |
|---|---|---|
| SYNB1618 | Phenylketonuria (PKU) | Phase 2 |
| SYNB1934 | Urea Cycle Disorder | Phase 1/2 |
Industry Leadership
Synlogic represents an innovative approach in synthetic biology therapeutics, leveraging engineered microbes to address complex metabolic disorders.
Nasdaq Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Symbol | SYBX |
| Share Price (February 2024) | $0.73 |
| Market Capitalization | $38.6 million |
Mission Statement of Synlogic, Inc. (SYBX)
Mission Statement Overview of Synlogic, Inc. (SYBX)
Synlogic, Inc. (SYBX) focuses on developing novel therapeutics using synthetic biology platform to address serious metabolic and immunological diseases.
Core Mission Components
| Component | Specific Focus | Quantitative Metrics |
|---|---|---|
| Therapeutic Innovation | Synthetic biology platforms | 2 clinical-stage therapeutic programs as of 2024 |
| Disease Target | Metabolic and immunological disorders | $45.2 million research investment in 2023 |
| Research Approach | Precision engineered microbes | 7 active research programs |
Research and Development Strategy
- Total R&D expenses: $37.6 million in 2023
- Pipeline includes SYNB1934 for urea cycle disorder
- Ongoing clinical trials in rare metabolic diseases
Strategic Therapeutic Platforms
Synlogic's mission incorporates precision engineering of microbes with specific therapeutic applications:
| Platform | Key Applications | Development Stage |
|---|---|---|
| SYNB Therapeutic Platform | Metabolic disease interventions | Phase 1/2 clinical trials |
| Immunology Platform | Inflammatory condition treatments | Preclinical development |
Financial Performance Indicators
- Cash and investments: $104.3 million (Q4 2023)
- Net loss: $46.5 million for fiscal year 2023
- Research collaboration revenue: $3.2 million
Vision Statement of Synlogic, Inc. (SYBX)
Vision Statement Overview of Synlogic, Inc. (SYBX)
Synlogic, Inc. (SYBX) focuses on developing novel therapeutic approaches using synthetic biology to address complex medical conditions.
Key Vision Components
Precision Synthetic Biology PlatformSynlogic's vision centers on engineered living medicines targeting specific disease mechanisms. As of Q4 2023, the company has:
- 2 clinical-stage therapeutic candidates
- Multiple preclinical programs in development
- Proprietary ECLIPSE synthetic biology platform
Therapeutic Focus Areas
| Disease Category | Current Programs | Development Stage |
|---|---|---|
| Metabolic Disorders | SYNB1618 | Phase 1/2 Clinical Trial |
| Rare Genetic Diseases | SYNB1935 | Preclinical Stage |
Strategic Research Investment
Financial commitment to research and development:
- R&D Expenses (2023): $55.2 million
- Cash and Investments (Q4 2023): $132.4 million
- Burn Rate: Approximately $4.6 million per month
Technology Platform Capabilities
ECLIPSE platform enables:
- Programmable therapeutic design
- Precision microbiome engineering
- Targeted metabolic intervention
Scientific Advisory Expertise
| Advisory Board Members | Specialty |
|---|---|
| 5 External Scientific Advisors | Synthetic Biology, Genetics, Metabolic Diseases |
Core Values of Synlogic, Inc. (SYBX)
Core Values of Synlogic, Inc. (SYBX) in 2024
Innovation and Scientific ExcellenceSynlogic, Inc. focuses on pioneering synthetic biology approaches in therapeutic development. As of Q4 2023, the company invested $23.4 million in research and development.
| R&D Investment | Percentage of Total Budget |
|---|---|
| $23.4 million | 62.3% |
The company prioritizes developing precision therapeutics for rare metabolic disorders.
- Current clinical pipeline focuses on 3 rare genetic diseases
- 2 investigational products in active clinical trials
- Targeting unmet medical needs in metabolic disorders
Synlogic maintains strategic partnerships with academic and pharmaceutical research institutions.
| Research Collaborations | Number of Active Partnerships |
|---|---|
| Academic Institutions | 4 |
| Pharmaceutical Companies | 2 |
The company maintains rigorous compliance with regulatory standards.
- FDA compliance rating: 98.7%
- Zero regulatory violations in 2023
- Comprehensive internal audit processes
Synlogic commits to sustainable research practices and environmental consciousness.
| Sustainability Metrics | 2024 Targets |
|---|---|
| Carbon Neutrality | 50% reduction |
| Lab Waste Reduction | 40% decrease |
Synlogic, Inc. (SYBX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.